1. Introduction
1.1. Market Scope and Segmental Definition
1.2. Assumptions & Limitation
2. Research Methodology
2.1. Research Approach & Data Sources
2.2. Forecasting Model
3. Executive Summary
3.1. Analyst?s Insights
3.2. Top Line Market estimation
3.3. Value Chain Analysis
4. Market Forces
4.1. Key Industry Drivers, Restraints and Opportunities
4.2. Industry Analysis
5. Market Outlook by Therapy (Current size & future market estimates)
5.1. Chemotherapy
5.2. Targeted therapy
5.3. Radiation therapy
5.4. Stem cell transplantation
6. Market Outlook by Type (Current size & future market estimates)
6.1. Philadelphia chromosome
6.2. Precursor B-cell ALL
6.3. T-cell ALL)
7. Market Outlook by End-use (Current size & future market estimates)
7.1. Hospital
7.2. Clinics
8. Market Outlook by Regions (Current size & future market estimates)
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. U.K.
8.2.3. France
8.3. APAC
8.3.1. Japan
8.3.2. China
8.3.3. India
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.5. MEA
8.5.1. South Africa
9. Competitive Landscape
9.1. Market Share/Market Ranking Analysis
9.2. Competitive Market Scenario (New Product Innovations, Key Strategic Moves & Partnerships, Start-up Ecosystem)
10. Company Profiles
Includes: Company Overview, Product & Services Offerings, Financials (only for listed companies), New Developments and Innovations
10.1. Erytech Pharma
10.2. Spectrum Pharmaceuticals, Inc.
10.3. Genmab A/S
10.4. Bristol-Myers Squibb Company
10.5. Pfizer, Inc.
10.6. Novartis AG
10.7. Celgene Corporation
10.8. Juno Therapeutics, Inc.